Skip to Content
Merck
CN
  • miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma.

miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma.

Oncology reports (2014-12-09)
Jiye Feng, Jinbo Wang, Mingliang Chen, Gun Chen, Zongyang Wu, Liping Ying, Qifeng Zhuo, Jianlei Zhang, Weilin Wang
ABSTRACT

miR-200a suppresses tumor development and progression; however, its role in tumor growth and metastasis of hepatocellular carcinoma (HCC) and the underlying mechanism have not been elucidated. In the present study, we identified that miR-200a was markedly downregulated in HCC and exerted suppressive effects on tumor cell growth and metastasis. We identified that miR-200a suppressed tumor growth and metastasis by directly targeting MACC1. In addition, HCC patients with low miR-200a expression had significantly worse prognosis than those with high expression of miR-200a. These findings suggest that miR-200a may be recognized as a novel potential biomarker to predict the survival of patients with HCCs following liver transplantation.

MATERIALS
Product Number
Brand
Product Description

Supelco
Digoxigenin, analytical standard
Sigma-Aldrich
Citrate Concentrated Solution, BioUltra, Molecular Biology, 1 M in H2O
Sigma-Aldrich
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
Supelco
Sodium Citrate, Pharmaceutical Secondary Standard; Certified Reference Material
Digoxigenin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Maleic acid, ReagentPlus®, ≥99% (HPLC)
Supelco
Maleic acid, qNMR standard, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
USP
Maleic acid, United States Pharmacopeia (USP) Reference Standard
Supelco
Maleic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Maleic acid, Vetec, reagent grade, 98%